-

11:43:04 PM

DBVT Stock News

DBVT - DBV Technologies

05/10/23 5:30 PM

Nasdaq : DBVT

clinical trial

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT TM ) with

RHEA-AI

neutral

05/09/23 4:30 PM

Nasdaq : DBVT

conferences

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, May 9, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences

RHEA-AI

neutral

05/04/23 4:30 PM

Nasdaq : DBVT

earnings

DBV Technologies Reports First Quarter 2023 Financial Results

Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today

RHEA-AI

neutral

04/19/23 5:09 PM

Nasdaq : DBVT

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint and did

RHEA-AI

very positive

04/12/23 4:30 PM

Nasdaq : DBVT

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical

RHEA-AI

neutral

03/24/23 4:30 PM

Nasdaq : DBVT

Ordinary and Extraordinary General Meeting of April 12, 2023

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical

RHEA-AI

neutral

03/13/23 1:30 AM

Nasdaq : DBVT

DBV Technologies Update

Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank. About DBV Technologies

RHEA-AI

neutral

03/07/23 4:30 PM

Nasdaq : DBVT

clinical trial

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois VITESSE is DBV’s Phase 3 clinical study evaluating the

RHEA-AI

neutral

03/02/23 5:30 PM

Nasdaq : DBVT

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

Montrouge, France, March 2, 2023 DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today

RHEA-AI

neutral

03/02/23 4:30 PM

Nasdaq : DBVT

earnings

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old DBV had $209.2 million in

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next